# Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing

> **NCT02353715** · — · COMPLETED · sponsor: **Duke University** · enrollment: 38 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Abiraterone acetate
- **DRUG:** Sipuleucel-T

## Key facts

- **NCT ID:** NCT02353715
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-07
- **Primary completion:** 2018-11-14
- **Final completion:** 2018-11-14
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02353715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02353715, "Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02353715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*